This post was originally published on this site
https://i-invdn-com.akamaized.net/news/World_News_9_M_1440052127.jpg
The drug, branded as Veklury, was being distributed across the United States by HHS.
Gilead said it is now meeting real-time demand for remdesivir in the U.S. and anticipates meeting global demand for the drug in October, even in the event of potential future surges of COVID-19.
Gilead donated courses of the drug after it was authorized in May for use in patients with a severe form of COVID-19. Trial data showed the antiviral drug helped shorten hospital recovery time.
AmerisourceBergen (NYSE:ABC) will continue to serve as the sole U.S. distributor of remdesivir through the end of this year and will sell the product directly to hospitals, Gilead said.
